Profit From New Must-Have Molecular Tests and Technologies

Hit clinical and financial home runs with intelligent use of emerging molecular assays and Technologies

YOUR PANEL OF EXPERTS:

Gregory Tsongalis, Ph.D., Director, Molecular Pathology, Dartmouth-Hitchcock Medical Center

Robert L. Michel, Editor-In-Chief, THE DARK REPORT

Molecular diagnostics is hot! Community hospital labs are using new molecular assays and technologies to help clinicians while at the same time earning higher reimbursements from payers. Find out how your laboratory can provide these brand-new molecular advances to your physicians—and significantly increase revenue—when you purchase the live audio recordings from the September 23rd DARK REPORT audio conference.

What are the best new molecular tests for your laboratory and the clinicians you serve in the community? How can new automated systems and analyzers make it easy for even mid-sized and smaller hospitals to offer fast, accurate molecular results? And which molecular tests are readily accepted by payers and generously reimbursed because of their unquestioned clinical utility?

Get answer to these questions, and more, when you register to attend “How Hospitals And Health System Labs Can Profit From New Must-Have Molecular Tests And Technologies.”

Your guide during this enlightening journey is Gregory Tsongalis, Ph.D. who is Director of Molecular Pathology at Dartmouth Hitchcock University in New Hampshire. He established the nation’s first molecular testing program in a community hospital more than ten years ago! As an expert in the field, Dr. Tsongalis understands the needs and financial constraints of community hospital laboratories so his recommendations, analysis and insights will help you set up a successful program for your community hospital or regional laboratory.

This comprehensive 90 minute audio conference recording will help you understand:

• New molecular applications, including MRSA, personalized medicine (pharmacogenomics, companion diagnostics), and why oncology is fast becoming the gold mine of molecular medicine.

• New automated systems and analyzers, with helpful hints about why “load and walk away” is helping even small hospital labs perform a surprisingly robust menu of molecular testing in-house.

• How to evaluate and select the best combination of new methodologies and automated instruments that work for your evolving molecular lab test menu.

Dr. Tsongalis is a frequent speaker at DARK REPORT events. He is a skilled facilitator who will help you understand the simple fundamentals that will allow you to establish a thriving in-house molecular testing program for your lab.

Best of all, our audio conference lets you gather your entire team together to listen, learn and ask questions. Plan now to be with us or order the audio CD from September 23rd and get the inside scoop on how your laboratory can use newly-introduced molecular tests and analyzers to give clinicians fast, vital results—while earning ample reimbursement from payers. This DARK REPORT and DARK DAILY audio conference, “How Hospitals And Health System Labs Can Profit From New Must-Have Molecular Tests And Technologies” is a sure bet to increase profits for your lab!

For one low price—just $245—you and your entire team can take part in this fast-paced, insightful audio conference.

Here’s just some of what you’ll learn during this insightful 90-minute conference:

• The latest in infectious disease testing, including rapid molecular assays with improved sensitivity and specificity.

• Why oncology is the exploding growth area in molecular—and which assays are “musts” for every community hospital lab.

• The differences between the newest automation solutions for sample preparation, interrogation, and detection, along with do’s and don’ts for purchasing these items.

• How managed care plans are covering and reimbursing for new molecular tests, and why payers want your hospital lab to perform certain in-house molecular assays.

• The secrets of using brand-new automated systems to expand your molecular testing program—without having to hire high-priced molecular med techs.

• The two most expensive errors that labs make when they establish or expand their molecular testing program.

• Why educating your referring physicians is a critical success factor for your hospital lab’s molecular testing program

…and much more. Order online now or call 800-560-6363.

YOUR PANEL OF EXPERTS:

Gregory Tsongalis, Ph.D. is certified as a high complexity clinical laboratory director. He is the Director of Molecular Pathology, Acting Director of Clinical Chemistry and co-director of the Pharmacogenomics program at the Dartmouth-Hitchcock Medical Center in New Hampshire. He received his Ph.D. in Pathology and Laboratory Medicine from the University of North Carolina at Chapel Hill. Dr. Tsongalis’ area of expertise is in clinical molecular diagnostic applications for genetic, hematologic, infectious and neoplastic diseases. His research interests are in the pathogenesis of solid tumors, disease association of SNP genotyping and personalized medicine. Dr. Tsongalis has authored/edited five textbooks in the field of molecular pathology, published more than 100 peer-reviewed manuscripts, and has been an invited speaker at both national and international meetings. Additionally, he has served on numerous committees of the AACC, AMP and ASIP and is the current AMP President

Robert L. Michel is Editor-in-Chief of THE DARK REPORT, an intelligence service and publication providing economic and strategic assessment of the clinical laboratory industry for senior executives and pathologists. He produces the “Executive War College on Laboratory and Pathology Management,” which has an international reputation as a source of innovative and effective management strategies and business models for pathologists and laboratory executives. Mr. Michel’s expertise is strategic analysis, corporate planning and market trend assessment. He was Director of Strategic Analysis and Special Projects for the regional laboratory division of Nichols Institute prior to and through its merger with Corning Clinical Laboratories (now Quest Diagnostics Incorporated). His corporate experience includes executive positions with Proctor & Gamble Distributing Company, Financial Corp. of America and Centex Corporation. In addition, he is a winner of the Newsletter and Electronic Publisher Association’s prestigious “Best Investigative Reporting” Award and is listed in Marquis Who’s Who in Healthcare and Medicine. Mr. Michel earned a B.A. in Economics from UCLA.